Chimeric Therapeutics Ltd

CHM

Company Profile

  • Business description

    Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

  • Contact

    62 Lygon Street
    Level 3, Carlton South
    MelbourneVIC3053
    AUS

    T: +61 398245254

    https://www.chimerictherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2025

    Employees

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,688.0035.50-0.41%
CAC 407,589.6636.210.48%
DAX 4023,350.55293.171.27%
Dow JONES (US)42,206.8235.160.08%
FTSE 1008,774.6517.15-0.20%
HKSE23,657.85127.370.54%
NASDAQ19,447.4198.86-0.51%
Nikkei 22538,354.0949.14-0.13%
NZX 50 Index12,532.6536.40-0.29%
S&P 5005,967.8413.03-0.22%
S&P/ASX 2008,474.9030.60-0.36%
SSE Composite Index3,382.0122.120.66%

Market Movers